

IN THE CLAIMS

Please cancel claims 19, 30 and 32 and amend claims 10, 12, and 28 as follows:

1-9. CANCELLED

10. (CURRENTLY AMENDED) Isolated GBP-4 guanylate binding protein-4 (GBP-4) polypeptide encoded by a nucleic acid comprising DNA having at least about 600 nucleotides and at least about a 95% sequence identity to (a) a DNA molecule encoding a human guanylate binding protein-4 (GBP-4) polypeptide comprising the sequence of amino acids 1-591 of Figure 1 (SEQ ID NO:3), wherein the guanylate binding protein-4 (GBP-4) polypeptide binds to at least one guanine nucleotide or (b) the complement of the DNA molecule of (a).

11. (ORIGINAL) The polypeptide of claim 10 that is human GBP-4.

12. (CURRENTLY AMENDED) A chimeric molecule comprising a guanylate binding protein-4 (GBP-4) polypeptide fused to a heterologous amino acid sequence, wherein the guanylate binding protein-4 (GBP-4) polypeptide binds to at least one guanine nucleotide.

13. (ORIGINAL) The chimeric molecule of claim 12 wherein said heterologous amino acid sequence is an epitope tag sequence or an Fc region of an immunoglobulin.

14-17. CANCELLED

18. (ORIGINAL) A composition comprising the polypeptide of claim 10 and a carrier therefor.

19. CANCELLED

20. (ORIGINAL) The composition of claim 18 further comprising GTP.

21-27. CANCELLED

28. (CURRENTLY AMENDED) An isolated GBP-4 guanylate binding protein-4 (GBP-4) polypeptide encoded by a nucleic acid which hybridizes under stringent conditions with the complementary strand of DNA encoding GBP-4 polypeptide comprising amino acids 1 to 591 of Figure 1 (SEQ ID NO: 3); wherein the GBP-4 polypeptide (a) binds to at least one guanine nucleotide; and (b) comprises:

- (i) a Asp-Thr-Glu-Gly (amino acid residues 97-100 of SEQ ID NO: 3) GTP binding consensus motif;
- (ii) a Thr-Leu-Arg-Asp (amino acid residues 179-182 of SEQ ID NO: 3) potential casein kinase II phosphorylation site;
- (iii) a Ser-Gly-Lys-Glu (amino acid residues 568-571 of SEQ ID NO: 3) potential casein kinase II phosphorylation site;
- (iv) a Thr-Leu-Arg (amino acid residues 179-181 of SEQ ID NO: 3) potential protein kinase C phosphorylation site;
- (v) a Thr-Met-Arg (amino acid residues 562-564 of SEQ ID NO: 3) potential protein kinase C phosphorylation site;
- (vi) a Ser-Gly-Lys (amino acid residues 568-570 of SEQ ID NO: 3) potential protein kinase C phosphorylation site;
- (vii) a Ser-Gln-Lys (amino acid residues 586-588 of SEQ ID NO: 3) potential protein kinase C phosphorylation site;
- (viii) a Gly-Ile-Met-Val-Asn-Gly (amino acid residues 283-288 of SEQ ID NO: 3) potential N-myristylation site;
- (ix) a Gly-Ser-Gln-Gln-Gly-Val (amino acid residues 579-584 of SEQ ID NO: 3) potential N-myristylation site; or
- (x) a Cys-Phe-Ile-Ser (amino acid residues 554-557 of SEQ ID NO: 3) potential prenylation site, wherein the stringent conditions are 0.015 M sodium chloride/0.0015 M sodium citrate/0.1% sodium dodecyl sulfate at 50°C.

29. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Cys-Phe-Ile-Ser (amino acid residues 554-557 of SEQ ID NO: 3) potential prenylation site.

30. CANCELLED

31. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Ser-Gly-Lys-Glu (amino acid residues 568-571 of SEQ ID NO: 3) potential casein kinase II phosphorylation site.

32. CANCELLED

33. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Thr-Met-Arg (amino acid residues 562-564 of SEQ ID NO: 3) potential protein kinase C phosphorylation site.

34. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Ser-Gly-Lys (amino acid residues 568-570 of SEQ ID NO: 3) potential protein kinase C phosphorylation site.

35. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Ser-Gln-Lys (amino acid residues 586-588 of SEQ ID NO: 3) potential protein kinase C phosphorylation site.

36. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Gly-Ile-Met-Val-Asn-Gly (amino acid residues 283-288 of SEQ ID NO: 3) potential N-myristoylation site.

37. (PREVIOUSLY PRESENTED) The GBP-4 polypeptide of claim 28, wherein the GBP-4 polypeptide comprises a Gly-Ser-Gln-Gln-Gly-Val (amino acid residues 579-584 of SEQ ID NO: 3) potential N-myristoylation site.